Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00153920 · BASELINE

Baseline characteristics

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma · Source last updated 2019-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      64
    units
    Participants
groups
  1. description
    Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
    id
    BG000
    title
    Bortezomib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          33
          upper Limit
          76
          value
          60
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          20
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          44
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          59
      title
      White
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      Non-White
    param Type
    NUMBER
    title
    Race/Ethnicity, Customized
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          64
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          32
      title
      ISS Stage I
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          26
      title
      ISS Stage II
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      ISS Stage III
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Unknown
    description
    International Staging System (ISS) Stage I: serum ß2-M \< 3.5 mg/L and serum albumin \>/= 3.5 g/dL Stage II: Neither stage I nor stage III Stage III: serum ß2-M \>/= 5.5 mg/L
    param Type
    NUMBER
    title
    ISS Stage
    unit Of Measure
    participants
population Description
The analysis population is comprised of eligible and treated participants.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      64
    units
    Participants
groups
  1. description
    Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
    id
    BG000
    title
    Bortezomib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          33
          upper Limit
          76
          value
          60
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          20
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          44
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          59
      title
      White
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      Non-White
    param Type
    NUMBER
    title
    Race/Ethnicity, Customized
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          64
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          32
      title
      ISS Stage I
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          26
      title
      ISS Stage II
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      ISS Stage III
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Unknown
    description
    International Staging System (ISS) Stage I: serum ß2-M \< 3.5 mg/L and serum albumin \>/= 3.5 g/dL Stage II: Neither stage I nor stage III Stage III: serum ß2-M \>/= 5.5 mg/L
    param Type
    NUMBER
    title
    ISS Stage
    unit Of Measure
    participants
population Description
The analysis population is comprised of eligible and treated participants.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice